Drug Reaction with Eosinophilia and Systemic Symptoms: An update on pathogenesis

Current Opinion in Immunology

Volumn 24, Issue 6, 2012, Pages 730-735

  Camous, Xavier ^a   Calbo, Sebastien ^a   Picard, Damien ^b   Musette, Philippe ^b  

^a AGENCY FOR SCIENCE   (Singapore)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN; CARBAMAZEPINE; GAMMA INTERFERON; HAPTEN; HLA B ANTIGEN; HLA B15 ANTIGEN; HLA B57 ANTIGEN; HLA B58 ANTIGEN; INTERLEUKIN 2; SULFAMETHOXAZOLE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE STORM; DRESS SYNDROME; DRUG ERUPTION; EPSTEIN BARR VIRUS; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HLA TYPING; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATHOGENESIS; REVIEW; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS; VIRUS REACTIVATION;

ANIMALS; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; DRUG TOXICITY; EOSINOPHILIA; HERPESVIRUS 4, HUMAN; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; T-LYMPHOCYTES; VIRUS ACTIVATION;

EID: 84869880272     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2012.07.010     Document Type: Review

References (53)

1. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., Halevy S., Davidovici B.B., Mockenhaupt M., Roujeau J.C. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol 2007, 156:609-611.
2. Shiohara T., Iijima M., Ikezawa Z., Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007, 156:1083-1084.
3. Gerber B.O., Pichler W.J. Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol 2004, 16:732-737.
4. Engler O.B., Strasser I., Naisbitt D.J., Cerny A., Pichler W.J. A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology 2004, 197:47-56.
5. Martin S.F., Esser P.R., Schmucker S., Dietz L., Naisbitt D.J., Park B.K., Vocanson M., Nicolas J.F., Keller M., Pichler W.J., et al. T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cell Mol Life Sci 2010, 67:4171-4184.
6. Chessman D., Kostenko L., Lethborg T., Purcell A.W., Williamson N.A., Chen Z., Kjer-Nielsen L., Mifsud N.A., Tait B.D., Holdsworth R., et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008, 28:822-832.
7. Hetherington S., Hughes A.R., Mosteller M., Shortino D., Baker K.L., Spreen W., Lai E., Davies K., Handley A., Dow D.J., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002, 359:1121-1122.
8. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., et al. Association between presence of HLA-B*5701 HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
9. Chung W.H., Hung S.I., Hong H.S., Hsih M.S., Yang L.C., Ho H.C., Wu J.Y., Chen Y.T. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004, 428:486.
10. Hung S.I., Chung W.H., Liou L.B., Chu C.C., Lin M., Huang H.P., Lin Y.L., Lan J.L., Yang L.C., Hong H.S., et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005, 102:4134-4139.
11. McCormack M., Alfirevic A., Bourgeois S., Farrell J.J., Kasperaviciute D., Carrington M., Sills G.J., Marson T., Jia X., de Bakker P.I., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.
12. Mallal S., Phillips E., Carosi G., Molina J.M., Workman C., Tomazic J., Jagel-Guedes E., Rugina S., Kozyrev O., Cid J.F., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
13. Kish D.D., Volokh N., Baldwin W.M., Fairchild R.L. Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cells. J Immunol 2011, 186:2117-2126.
14. Elsheikh A., Lavergne S.N., Castrejon J.L., Farrell J., Wang H., Sathish J., Pichler W.J., Park B.K., Naisbitt D.J. Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism. J Immunol 2010, 185:6448-6460.
15. Gaedigk A., Spielberg S.P., Grant D.M. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994, 4:142-153.
16. Green V.J., Pirmohamed M., Kitteringham N.R., Gaedigk A., Grant D.M., Boxer M., Burchell B., Park B.K. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol 1995, 50:1353-1359.
17. Zanni M.P., Schnyder B., von Greyerz S., Pichler W.J. Involvement of T cells in drug-induced allergies. Trends Pharmacol Sci 1998, 19:308-310.
18. Pichler W.J. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002, 2:301-305.
19. Illing P.T., Vivian J.P., Dudek N.L., Kostenko L., Chen Z., Bharadwaj M., Miles J.J., Kjer-Nielsen L., Gras S., Williamson N.A., et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012, 486:554-558.
20. Ostrov D.A., Grant B.J., Pompeu Y.A., Sidney J., Harndahl M., Southwood S., Oseroff C., Lu S., Jakoncic J., de Oliveira C.A., et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 2012, 109:9959-9964.
21. Wei C.-Y., Chung W.-H., Huang H.-W., Chen Y.-T., Hung S.-I. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012, 129:e1565.
22. Sekine N., Motokura T., Oki T., Umeda Y., Sasaki N., Hayashi M., Sato H., Fujita T., Kaneko T., Asano Y., et al. Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA 2001, 285:1153-1154.
23. Kano Y., Sakuma K., Shiohara T. Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity syndrome. Br J Dermatol 2007, 156:1061-1063.
24. Chen P., Lin J.J., Lu C.S., Ong C.T., Hsieh P.F., Yang C.C., Tai C.T., Wu S.L., Lu C.H., Hsu Y.C., et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011, 364:1126-1133.
25. Bharadwaj M., Illing P., Theodossis A., Purcell A.W., Rossjohn J., McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 2012, 52:401-431.
26. Descamps V., Valance A., Edlinger C., Fillet A.M., Grossin M., Lebrun-Vignes B., Belaich S., Crickx B. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001, 137:301-304.
27. Seishima M., Yamanaka S., Fujisawa T., Tohyama M., Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 2006, 155:344-349.
28. Kano Y., Hiraharas K., Sakuma K., Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006, 155:301-306.
29. Shiohara T., Inaoka M., Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006, 55:1-8.
30. Descamps V., Bouscarat F., Laglenne S., Aslangul E., Veber B., Descamps D., Saraux J.L., Grange M.J., Grossin M., Navratil E., et al. Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome. Br J Dermatol 1997, 137:605-608.
31. Salahuddin S.Z., Ablashi D.V., Markham P.D., Josephs S.F., Sturzenegger S., Kaplan M., Halligan G., Biberfeld P., Wong-Staal F., Kramarsky B., et al. Isolation of a new virus HBLV, in patients with lymphoproliferative disorders. Science 1986, 234:596-601.
32. Ensoli B., Lusso P., Schachter F., Josephs S.F., Rappaport J., Negro F., Gallo R.C., Wong-Staal F. Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer. EMBO J 1989, 8:3019-3027.
33. Challoner P.B., Smith K.T., Parker J.D., MacLeod D.L., Coulter S.N., Rose T.M., Schultz E.R., Bennett J.L., Garber R.L., Chang M., et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995, 92:7440-7444.
34. Buchwald D., Cheney P.R., Peterson D.L., Henry B., Wormsley S.B., Geiger A., Ablashi D.V., Salahuddin S.Z., Saxinger C., Biddle R., et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 1992, 116:103-113.
35. Sashihara J., Tanaka-Taya K., Tanaka S., Amo K., Miyagawa H., Hosoi G., Taniguchi T., Fukui T., Kasuga N., Aono T., et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood 2002, 100:2005-2011.
36. Donati D., Akhyani N., Fogdell-Hahn A., Cermelli C., Cassiani-Ingoni R., Vortmeyer A., Heiss J.D., Cogen P., Gaillard W.D., Sato S., et al. Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections. Neurology 2003, 61:1405-1411.
37. Kofman A., Marcinkiewicz L., Dupart E., Lyshchev A., Martynov B., Ryndin A., Kotelevskaya E., Brown J., Schiff D., Abounader R. The roles of viruses in brain tumor initiation and oncomodulation. J Neurooncol 2011, 105:451-466.
38. Flamand L., Romerio F., Reitz M.S., Gallo R.C. CD4 promoter transactivation by human herpesvirus 6. J Virol 1998, 72:8797-8805.
39. Mardivirin L., Valeyrie-Allanore L., Branlant-Redon E., Beneton N., Jidar K., Barbaud A., Crickx B., Ranger-Rogez S., Descamps V. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro. Eur J Dermatol 2010, 20:68-73.
40. Kano Y., Shiohara T. Sequential reactivation of herpesvirus in drug-induced hypersensitivity syndrome. Acta Derm Venereol 2004, 84:484-485.
41. Kano Y., Horie C., Inaoka M., Tadashi I., Mizukawa Y., Shiohara T. Herpes zoster in patients with drug-induced hypersensitivity syndrome/DRESS. Acta Derm Venereol 2012, 92:206-207.
42. Picard D., Janela B., Descamps V., D'Incan M., Courville P., Jacquot S., Rogez S., Mardivirin L., Moins-Teisserenc H., Toubert A., et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010, 2:46ra62.
43. Teraki Y., Murota H., Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008, 144:232-235.
44. Aihara Y., Ito S., Kobayashi Y., Aihara M. Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection. Allergy 2004, 59:118.
45. Takahashi R., Kano Y., Yamazaki Y., Kimishima M., Mizukawa Y., Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009, 182:8071-8079.
46. Otani N., Okuno T. Human herpesvirus 6 infection of CD4+ T-cell subsets. Microbiol Immunol 2007, 51:993-1001.
47. Cribb A.E., Spielberg S.P., Griffin G.P. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995, 23:406-414.
48. Cribb A.E., Miller M., Tesoro A., Spielberg S.P. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol Pharmacol 1990, 38:744-751.
49. Schnyder B., Burkhart C., Schnyder-Frutig K., von Greyerz S., Naisbitt D.J., Pirmohamed M., Park B.K., Pichler W.J. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol 2000, 164:6647-6654.
50. Lavergne S.N., Wang H., Callan H.E., Park B.K., Naisbitt D.J. " Danger" conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J Pharmacol Exp Ther 2009, 331:372-381.
51. Callan H.E., Jenkins R.E., Maggs J.L., Lavergne S.N., Clarke S.E., Naisbitt D.J., Park B.K. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol 2009, 22:937-948.
52. Carballal S., Radi R., Kirk M.C., Barnes S., Freeman B.A., Alvarez B. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry 2003, 42:9906-9914.
53. Saurin A.T., Neubert H., Brennan J.P., Eaton P. Widespread sulfenic acid formation in tissues in response to hydrogen peroxide. Proc Natl Acad Sci U S A 2004, 101:17982-17987.